NASDAQ Composite opens in less than one hour and Moderna’s pre-market value is already 3.8% up.
The last session, NASDAQ Composite ended with Moderna dropping 1.47% to $131.02. NASDAQ Composite dropped 0% to $13,543.06, after four sequential sessions in a row of gains, on what was a somewhat positive trend trading session.
Moderna’s last close was $132.98, 36.24% below its 52-week high of $178.50.
Moderna’s sales growth is 1986.4% for the current quarter and 19117.5% for the next. The company’s growth estimates for the present quarter and the next is 18.9% and 660%, respectively.
Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.
Moderna’s Stock Yearly Top and Bottom Value
Moderna’s stock is valued at $131.02 at 08:52 EST, way under its 52-week high of $178.50 and way above its 52-week low of $17.91.
Moderna’s Moving Average
Moderna’s value is under its 50-day moving average of $132.26 and way above its 200-day moving average of $89.14.
Moderna’s last day, last week, and last month’s average volatility was a positive 6.26%, a positive 1.43%, and a negative 0.27%, respectively.
Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 9.38%, 5.86%, and 8.06%, respectively.
Previous days news about Moderna
Moderna lags in WHO vaccine drive as Chinese shots near approval. According to Bloomberg Quint on Friday, 22 January, "This is despite the fact that Moderna is one of 11 vaccine candidates that received funding from the WHO-backed Coalition for Epidemic Preparedness, though the $1 million provided paled in comparison to the hundreds of millions the company received from the U.S. government’s Operation Warp Speed.", "The company is in dialogue with the WHO and is committed to a successful outcome, a Moderna spokesman said in an emailed statement to Bloomberg News, without giving further details."
CDC finds one in 400,000 had anaphylaxis after Moderna shot. According to Bloomberg Quint on Friday, 22 January, "The CDC’s Nordlund said that as of Jan. 19, there have been 15 cases of anaphylaxis with the Moderna shot and 45 with the Pfizer shot, rates of 2.1 cases per million doses and 6.2 cases per million doses, respectively. ", "All 10 patients who experienced anaphylaxis after receiving the Moderna shot were treated with epinephrine. "